Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting in Torino, Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and AD/PD™.
Alessandro Padovani M.D., Ph.D., professor of neurology and director of the Institute of Neurology at the Università degli Studi di Brescia, will open the meeting discussing the importance of early identification and treatment of Alzheimer’s disease. His discussion will include Centiloid, a method used to standardize the aducanumab Phase 1b study amyloid PET results as previously measured by the composite Standardized Uptake Value Ratio (SUVR). At 54 weeks, the treatment group receiving the highest dose of aducanumab (10 mg/kg) experienced a 69% reduction from baseline in amyloid plaque as observed on the Centiloid Conversion scale (P<0.001 versus placebo). There was no change from baseline in the placebo arm.
In the Phase 1b long-term extension (LTE), the most commonly reported adverse events were headache, fall, and amyloid-related imaging abnormalities (ARIA). Of the 185 patients dosed with aducanumab in the Phase 1b study, 46 patients experienced ARIA-E (edema). There were no new cases of ARIA-E in patients who continued on the same dose of aducanumab.
“Biogen is working to solve some of medicine’s greatest challenges among the most complex, devastating neurodegenerative diseases,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “As pioneers in neuroscience with 40 years of expertise we remain committed to tackling areas of high unmet medical need such as Alzheimer’s disease and movement disorders including Parkinson’s disease and progressive supranuclear palsy.”
The planned Alzheimer’s disease presentations include:
- The Importance of Early Identification and Treatment of Alzheimer’s disease. Plenary Session; March 15, 2018, 13:00 – 13:30 CET.
- The early diagnosis of Alzheimer’s disease: It’s about time. Biogen Sponsored Symposium; March 16, 2018, 11:45 – 13:25 CET.
- Aducanumab interim analysis from PRIME: A randomized, double-blind, placebo-controlled Phase 1B study in patients with prodromal or mild Alzheimer’s disease. Symposium Session 13; March 16, 2018, 16:45 – 17:05 CET.
The planned movement disorders presentations include:
- Neuromelanin-sensitive MRI as a potential biomarker for Parkinson’s disease. Poster 114; March 15, 2018, 8:00 – 18:00 CET.
- Wearable sensors for quantitative gait characteristics in clinical trials of Parkinson’s disease. Poster 129; March 15, 2018, 8:00 – 18:00 CET.
- Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: PASSPORT Phase 2 study design. Symposium Session 18; March 17, 2018, 9:45 – 10:05 CET.
Biogen will participate in two panel discussions:
- Forum discussion 2 – AD Phase III Clinical Trials. Panel Discussion; March 16, 2018, 14:25 – 15:25 CET.
- Forum on novel approaches to disease-modifying therapies of Parkinson’s disease (PD) and Lewy Body Disease (LBD). Panel Discussion; March 17, 2018, 14:00 – 15:00 CET.
The “Importance of Early Identification and Treatment of Alzheimer’s disease” Plenary Session will be webcast live. To access the live webcast, please visit the Investors section of Biogen’s website at www.biogen.com/investors. An archived version of the webcast will be available following the presentation.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about additional results from the Phase 1b study of aducanumab, the potential clinical effects of aducanumab and/or BIIB092, the identification and treatment of Alzheimer’s disease as well as clinical studies on Parkinson’s disease and progressive supranuclear palsy. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, the occurrence of adverse safety events, or we may encounter other unexpected hurdles. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Amazon Studios Greenlights Utopia, Signs Gillian Flynn to Overall Deal19.4.2018 13:00 | Pressemelding
(NASDAQ: AMZN)— Amazon Studios announced today that it has greenlit a straight-to-series order for Utopia, a nine-episode series from award-winning Gillian Flynn, the best-selling author and screenwriter of Golden Globe nominated Gone Girl and HBO’s highly anticipated Sharp Objects. Flynn has also inked an overall deal with Amazon Studios across television, marking Utopia as the first project. Utopia will be available exclusively on Prime Video in more than 200 countries and territories. Utopia is based on the British series of the same name written by Dennis Kelly. The series is a co-production between Endemol Shine North America and Kudos, an Endemol Shine Group UK production studio, and Amazon Studios. A group of young adults, who meet online, are mercilessly hunted by a shadowy deep state organization after they come in to possession of a near mythical cult underground graphic novel – they discover the conspiracy theories in the comic’s pages may actually be real and are forced in
Yourtyres.co.uk at The Tire Cologne 2018: Concepts for Linking Online and Offline Business19.4.2018 12:47 | Pressemelding
Delticom AG/Yourtyres.co.uk. At this year’s Tire Cologne trade fair, Yourtyres.co.uk will be presenting its partnership model, which focuses on the linking of online and offline trade. Yourtyres.co.uk is the online wholesale shop from Europe’s largest tyre retailer, Delticom. From 29th May to 1st June, visitors to the fair can learn how workshops and stationary tyre retailers are able to benefit from the increasing amount of online trade without having to give up their independence. This is because Yourtyres.co.uk offers its wholesale customers excellent terms of purchase and high flexibility. There are no minimum purchase levels, and customers are not obliged to stock specific brands. There are also no contract costs or commissions. Using the Yourtyres.co.uk website and placing orders are completely free of charge. Customers benefit from the shop’s wide range of car, truck and motorbike tyres, as well as high availability all year round thanks to Delticom’s in-house warehousing and in
Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine19.4.2018 11:48 | Pressemelding
Flowsion, the Denmark-based developer of continuous blood glucose systems for intensive care medicine, has won a prestigious European Commission Horizon 2020 SME Instrument award. The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies. “It’s a welcome validation of our innovative, patented technology and a confirmation that we are addressing a really significant problem with a globally-relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we now that Glucostat will fulfil the demands of the intensive care units.” With 5-8 % success rate the European Innovation Council SME Instrument awards are exceptionally competitive, and only 3018 companies across Eu
Nexperia Secures $800M Financing to Fund Future Growth Plans19.4.2018 09:33 | Pressemelding
Nexperia, the global leader in discretes, logic and MOSFET devices, today announced the successful completion of a refinancing of its current facilities with USD 800 million equivalent of senior credit facilities. This includes a significant proportion of Revolving Credit facility. The proceeds will be used to refinance existing outstanding debt and for Capex expenditure to fund future growth. The facilities were arranged by Bank of America Merrill Lynch and HSBC, acting as Global Coordinators, and were syndicated by a group of nine global banks. The refinancing is fully supported by JAC Capital and Wise Road Capital, Nexperia’s two main shareholders, and provides a flexible financing package at very attractive terms to support the further growth of Nexperia going forward. Comments from Frans Scheper, Nexperia’s CEO: “This is the first time that Nexperia has approached the financial markets as an independent company, so we are very pleased with the enthusiastic response. Refinancing th
Grundig – Redefining Kitchen Design and Technology19.4.2018 09:19 | Pressemelding
UNLEASH YOUR GOURMET CAPABILITIES WITH GRUNDIG’S GOURMET CHEF™ OVEN This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005580/en/ (Photo: Grundig) Grundig’s Gourmet Chef™ Oven makes cooking elaborate, delicious meals easier than ever before. The oven’s intuitive design and innovative technology combine to simplify cooking and cleaning processes, inspire culinary creativity, and produce exquisite results. Equipped with advanced connected technologies and sensors, it allows users to precisely control the temperature of their food as it cooks to ensure the best results. This includes a high temperature moisture sensor, a temperature control sensor and BLDC motor, an integrated camera and a multipoint meat probe. Cleaning up after your culinary creation couldn’t be easier for users, with the oven fitted with advanced automatic self cleaning, including water and high-pressure steam cleaning, The Gourmet Chef™ elegant and sophis
PIXID Continues European Expansion with Acquisition of Dutch Staffing CRM Supplier Carerix19.4.2018 09:09 | Pressemelding
European workforce management solutions provider PIXID, has acquired Carerix, a Dutch-based CRM and ATS supplier, to further strengthen its proposition and expand its operations. Adding a leading supplier for CRM and ATS systems to its ranks allows PIXID to reinforce its expertise, enhance its service offering and strengthen the value chain offered to the temporary employment sector. The purchase also means PIXID can now add a presence in Benelux to its existing offices in France, in the UK (since its acquisition of The Internet Corporation in 2017) and its operations in Germany. A complete online software solution for recruitment and staffing agencies, Carerix is currently helping more than 10,000 users every day. It has a presence in 17 countries due to high-profile relationships with major customers including Randstad, Adecco, Manpower, T-Groep and DPA. Carerix has a multi-level partnership programme and an ecosystem which allows for a tailored offering and broader promotion of its